Nuveen LLC Invests $1.07 Million in Savara Inc. $SVRA

Nuveen LLC acquired a new stake in shares of Savara Inc. (NASDAQ:SVRA - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 385,103 shares of the company's stock, valued at approximately $1,067,000. Nuveen LLC owned approximately 0.22% of Savara as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in SVRA. Wells Fargo & Company MN boosted its stake in shares of Savara by 42.9% during the 4th quarter. Wells Fargo & Company MN now owns 59,277 shares of the company's stock valued at $182,000 after buying an additional 17,786 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Savara in the 4th quarter valued at $798,000. Barclays PLC lifted its position in shares of Savara by 2.5% in the fourth quarter. Barclays PLC now owns 236,705 shares of the company's stock worth $728,000 after buying an additional 5,700 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock valued at $441,000 after acquiring an additional 5,450 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in Savara in the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Stock Performance

NASDAQ SVRA traded up $0.16 on Thursday, hitting $3.58. 1,775,465 shares of the stock were exchanged, compared to its average volume of 1,278,539. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $4.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The company has a market capitalization of $618.76 million, a PE ratio of -7.16 and a beta of 0.56. The business's fifty day moving average is $2.66 and its 200 day moving average is $2.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Research analysts anticipate that Savara Inc. will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Savara news, Director Richard J. Hawkins acquired 48,225 shares of the company's stock in a transaction on Friday, June 20th. The stock was acquired at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director directly owned 115,466 shares of the company's stock, valued at $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.33% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on SVRA. Wells Fargo & Company decreased their price objective on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. Evercore ISI decreased their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday, May 28th. HC Wainwright raised their target price on Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a research report on Wednesday. Guggenheim reaffirmed a "buy" rating and set a $8.00 price objective (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Finally, Oppenheimer lifted their price target on Savara from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, August 15th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $6.67.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.